Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Injectable semaglutide at equivalent therapeutic doses (2.4mg weekly Wegovy) produces average weight loss of 14.9% over 68 weeks in clinical trials
Tetsuya Akaishi of the Department of Neurology, Tohoku University School of Medicine, Sendai, Japan, led the study
J Integr Med
GLP-1 Market Size, Share & Trends Analysis Report By Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist, Short-acting GLP-1 Agonist), By Type of Agonist (Single Agonist, Dual Agonist, Tri-agonist), By Molecule Type (Biologic Peptide GLP-1 Agonists, Small-Molecule Non-Peptide GLP-1 Agonists), By Active Compound (Semaglutide, Tirzepatide, Dulaglutide, Liraglutide, Lixisenatide, Exenatide, Orforglipron, Retatrutide, Survodutide, Other Active Compounds), By Route of Administration (Oral, Parenteral), By Dosing Frequency (Daily, Weekly, Monthly or Extended-Interval), By Delivery System, By Target Indication, By Payer, By Region and By Segments Forecasts, 2026 to 2035
People reach for it to clean, rinse their hair, preserve food, support their health, and care for their skin
US$ 25.23
US$ 20.49
US$ 26.76
